Dr. Kevin Alexander and Dr. C. Michael Gibson discuss: Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.